phosphorylcholine has been researched along with Inflammation in 55 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to report a retrospective case series of anterior scleral and limbal inflammatory necrosis after adjuvant miltefosine for recalcitrant Acanthamoeba keratitis (AK)." | 8.12 | Anterior Scleral and Limbal Inflammatory Necrosis After Adjuvant Miltefosine for Recalcitrant Acanthamoeba Keratitis. ( Berdahl, J; de la Presa, M; Holland, EJ; Ibach, M, 2022) |
| "We tested the effect of miltefosine on the activation of human eosinophils and their effector responses in vitro and in mouse models of eosinophilic migration and ovalbumin-induced allergic lung inflammation." | 8.02 | The anti-parasitic drug miltefosine suppresses activation of human eosinophils and ameliorates allergic inflammation in mice. ( Heinemann, A; Kienzl, M; Knuplez, E; Marsche, G; Schicho, R; Sturm, EM; Trakaki, A, 2021) |
| "Miltefosine inhibits T-cell proliferation and effectively reduces inflammation in the T-cell transfer model." | 7.79 | Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease. ( Duijvestein, M; Hommes, DW; Meijer, SL; Peppelenbosch, MP; te Velde, AA; van den Brink, GR; Verhaar, AP; Vos, AC; Wildenberg, ME, 2013) |
| " The purpose of this study was to determine the efficacy of local methylprednisolone (MP) delivery using PC-coated stents to inhibit inflammatory response and in-stent neointimal hyperplasia in an overstretched porcine coronary model." | 7.72 | Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model. ( De Scheerder, I; Huang, Y; Li, S; Liu, X; Verbeken, E; Wang, L, 2003) |
| "We demonstrate that miltefosine is locally active in patients with AD and led to a sustained clinical improvement in local skin inflammation." | 5.14 | Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis. ( Dölle, S; Hoser, D; Loddenkemper, C; Maurer, M; Rasche, C; Worm, M; Zuberbier, T, 2010) |
| "The purpose of this study was to report a retrospective case series of anterior scleral and limbal inflammatory necrosis after adjuvant miltefosine for recalcitrant Acanthamoeba keratitis (AK)." | 4.12 | Anterior Scleral and Limbal Inflammatory Necrosis After Adjuvant Miltefosine for Recalcitrant Acanthamoeba Keratitis. ( Berdahl, J; de la Presa, M; Holland, EJ; Ibach, M, 2022) |
| "We tested the effect of miltefosine on the activation of human eosinophils and their effector responses in vitro and in mouse models of eosinophilic migration and ovalbumin-induced allergic lung inflammation." | 4.02 | The anti-parasitic drug miltefosine suppresses activation of human eosinophils and ameliorates allergic inflammation in mice. ( Heinemann, A; Kienzl, M; Knuplez, E; Marsche, G; Schicho, R; Sturm, EM; Trakaki, A, 2021) |
| "Miltefosine inhibits T-cell proliferation and effectively reduces inflammation in the T-cell transfer model." | 3.79 | Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease. ( Duijvestein, M; Hommes, DW; Meijer, SL; Peppelenbosch, MP; te Velde, AA; van den Brink, GR; Verhaar, AP; Vos, AC; Wildenberg, ME, 2013) |
| "To assess the effect of irinotecan-eluting stents (IS) on neointimal growth in the aortas of hypercholesterolemic rabbits and to determine other local histopathological effects such as necrosis, fibrin, and inflammatory reaction." | 3.73 | Irinotecan-eluting stents inhibited neointimal proliferation in hypercholesterolemic rabbit aortas. ( Berrocal, DH; Gelpi, RJ; González, GE; Grinfeld, LR; Morales, C, 2006) |
| " The purpose of this study was to determine the efficacy of local methylprednisolone (MP) delivery using PC-coated stents to inhibit inflammatory response and in-stent neointimal hyperplasia in an overstretched porcine coronary model." | 3.72 | Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model. ( De Scheerder, I; Huang, Y; Li, S; Liu, X; Verbeken, E; Wang, L, 2003) |
| "Atherosclerosis is the main cause of CVD in the general population, and in SLE, increased atherosclerosis, especially the prevalence of atherosclerotic plaques, has been demonstrated." | 3.01 | Systemic lupus erythematosus and cardiovascular disease. ( Frostegård, J, 2023) |
| "Pain is a sensation a humans sense as a protective mechanism against physical injury." | 1.72 | Impact of Olive Oil Constituents on C-reactive Protein: In silico Evidence. ( Afzal, M; Asaruddin, MR; Khan, MSA; Mahmood, MH; Rahman, HU; Sama, NU, 2022) |
| "Phosphorylcholine is a pro-inflammatory epitope exposed on apoptotic cells, and phosphorylcholine monoclonal immunoglobulin (Ig)G antibodies (PC-mAb) have anti-inflammatory properties." | 1.62 | Phosphorylcholine antibodies restrict infarct size and left ventricular remodelling by attenuating the unreperfused post-ischaemic inflammatory response. ( Atsma, DE; de Jong, RCM; de Vries, MR; Jukema, JW; Pettersson, K; Pluijmert, NJ; Quax, PHA, 2021) |
| "Inflammation has an important function in the development of cerebral vasospasm after subarachnoid hemorrhage (SAH); however, the mediators of this inflammatory response have not been clearly identified." | 1.37 | Sphingosylphosphorylcholine is a proinflammatory mediator in cerebral arteries. ( Hunter, I; Mathieson, FA; Nixon, GF; Wirrig, C, 2011) |
| " This alkylphospholipid was also extremely toxic against intracellular amastigotes of both strains." | 1.31 | Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. ( Bozza, MT; Freire-De-Lima, CG; Gibaldi, D; Heise, N; Mendonça-Previato, L; Previato, JO; Saraiva, VB, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.82) | 18.7374 |
| 1990's | 1 (1.82) | 18.2507 |
| 2000's | 12 (21.82) | 29.6817 |
| 2010's | 25 (45.45) | 24.3611 |
| 2020's | 16 (29.09) | 2.80 |
| Authors | Studies |
|---|---|
| de la Presa, M | 1 |
| Ibach, M | 1 |
| Berdahl, J | 1 |
| Holland, EJ | 1 |
| Frostegård, J | 4 |
| Kim, DS | 1 |
| Na, HS | 1 |
| Cho, KH | 1 |
| Lee, KH | 1 |
| Choi, J | 1 |
| Kwok, SK | 1 |
| Bae, YS | 1 |
| Cho, ML | 1 |
| Park, SH | 1 |
| Chu, KO | 1 |
| Chan, KP | 1 |
| Yip, YWY | 1 |
| Chu, WK | 1 |
| Wang, CC | 1 |
| Pang, CP | 1 |
| Rahman, HU | 1 |
| Mahmood, MH | 1 |
| Sama, NU | 1 |
| Afzal, M | 1 |
| Asaruddin, MR | 1 |
| Khan, MSA | 1 |
| Ullah, N | 1 |
| Wu, Y | 1 |
| Dix, C | 1 |
| Zeller, J | 6 |
| Stevens, H | 1 |
| Eisenhardt, SU | 7 |
| Shing, KSCT | 1 |
| Nero, TL | 5 |
| Morton, CJ | 5 |
| Parker, MW | 5 |
| Peter, K | 7 |
| McFadyen, JD | 4 |
| Alic, L | 1 |
| Binder, CJ | 2 |
| Papac-Milicevic, N | 1 |
| Cheung Tung Shing, KS | 3 |
| Krippner, G | 3 |
| Bogner, B | 3 |
| Kreuzaler, S | 3 |
| Kiefer, J | 4 |
| Horner, VK | 3 |
| Braig, D | 5 |
| Danish, H | 3 |
| Baratchi, S | 3 |
| Fricke, M | 3 |
| Wang, X | 5 |
| Kather, MG | 3 |
| Kammerer, B | 3 |
| Woollard, KJ | 4 |
| Sharma, P | 3 |
| Pietersz, G | 3 |
| Zheng, Y | 1 |
| Yang, J | 1 |
| Liang, J | 1 |
| Xu, X | 1 |
| Cui, W | 1 |
| Deng, L | 1 |
| Zhang, H | 1 |
| Pisipati, S | 1 |
| Connor, BA | 1 |
| Riddle, MS | 1 |
| Knuplez, E | 1 |
| Kienzl, M | 1 |
| Trakaki, A | 1 |
| Schicho, R | 1 |
| Heinemann, A | 1 |
| Sturm, EM | 1 |
| Marsche, G | 1 |
| Simpson, FC | 1 |
| McTiernan, CD | 1 |
| Islam, MM | 1 |
| Buznyk, O | 1 |
| Lewis, PN | 1 |
| Meek, KM | 1 |
| Haagdorens, M | 1 |
| Audiger, C | 1 |
| Lesage, S | 1 |
| Gueriot, FX | 1 |
| Brunette, I | 1 |
| Robert, MC | 1 |
| Olsen, D | 1 |
| Koivusalo, L | 1 |
| Liszka, A | 1 |
| Fagerholm, P | 1 |
| Gonzalez-Andrades, M | 1 |
| Griffith, M | 1 |
| Pluijmert, NJ | 1 |
| de Jong, RCM | 1 |
| de Vries, MR | 1 |
| Pettersson, K | 1 |
| Atsma, DE | 1 |
| Jukema, JW | 1 |
| Quax, PHA | 1 |
| Qiao, Y | 1 |
| Zhang, Q | 1 |
| Wang, Q | 1 |
| Lin, J | 1 |
| Wang, J | 1 |
| Li, Y | 1 |
| Wang, L | 3 |
| Kim, SJ | 1 |
| Song, YS | 1 |
| Pham, TH | 1 |
| Bak, Y | 1 |
| Lee, HP | 1 |
| Hong, JT | 1 |
| Yoon, DY | 1 |
| Que, X | 1 |
| Hung, MY | 1 |
| Yeang, C | 1 |
| Gonen, A | 1 |
| Prohaska, TA | 1 |
| Sun, X | 1 |
| Diehl, C | 1 |
| Määttä, A | 1 |
| Gaddis, DE | 1 |
| Bowden, K | 1 |
| Pattison, J | 1 |
| MacDonald, JG | 1 |
| Ylä-Herttuala, S | 1 |
| Mellon, PL | 1 |
| Hedrick, CC | 1 |
| Ley, K | 1 |
| Miller, YI | 1 |
| Glass, CK | 1 |
| Peterson, KL | 1 |
| Tsimikas, S | 1 |
| Witztum, JL | 1 |
| Segal, Y | 1 |
| Blank, M | 1 |
| Shoenfeld, Y | 1 |
| Newling, M | 1 |
| Sritharan, L | 1 |
| van der Ham, AJ | 1 |
| Hoepel, W | 1 |
| Fiechter, RH | 1 |
| de Boer, L | 1 |
| Zaat, SAJ | 1 |
| Bisoendial, RJ | 1 |
| Baeten, DLP | 1 |
| Everts, B | 1 |
| den Dunnen, J | 1 |
| López, P | 1 |
| Rodríguez-Carrio, J | 1 |
| Martínez-Zapico, A | 1 |
| Pérez-Álvarez, ÁI | 1 |
| Benavente, L | 1 |
| Caminal-Montero, L | 1 |
| Suárez, A | 1 |
| Sharif, O | 1 |
| Matt, U | 1 |
| Saluzzo, S | 1 |
| Lakovits, K | 1 |
| Haslinger, I | 1 |
| Furtner, T | 1 |
| Doninger, B | 1 |
| Knapp, S | 1 |
| Verhaar, AP | 1 |
| Wildenberg, ME | 1 |
| te Velde, AA | 1 |
| Meijer, SL | 1 |
| Vos, AC | 1 |
| Duijvestein, M | 1 |
| Peppelenbosch, MP | 1 |
| Hommes, DW | 1 |
| van den Brink, GR | 1 |
| Thiele, JR | 3 |
| Habersberger, J | 1 |
| Schmidt, Y | 1 |
| Goerendt, K | 1 |
| Maurer, V | 1 |
| Bannasch, H | 2 |
| Scheichl, A | 1 |
| von Dobschütz, E | 1 |
| Kolodgie, F | 1 |
| Virmani, R | 1 |
| Stark, GB | 3 |
| Taniguchi, K | 1 |
| Hikiji, H | 1 |
| Okinaga, T | 1 |
| Hashidate-Yoshida, T | 1 |
| Shindou, H | 1 |
| Ariyoshi, W | 1 |
| Shimizu, T | 1 |
| Tominaga, K | 1 |
| Nishihara, T | 1 |
| El-Najjar, N | 1 |
| Orsó, E | 1 |
| Wallner, S | 1 |
| Liebisch, G | 1 |
| Schmitz, G | 1 |
| Hatemi, AC | 1 |
| Çeviker, K | 1 |
| Tongut, A | 1 |
| Özgöl, İ | 1 |
| Mert, M | 1 |
| Kaya, A | 1 |
| Tan, X | 1 |
| Zhan, J | 1 |
| Zhu, Y | 1 |
| Cao, J | 1 |
| Liu, S | 1 |
| Wang, Y | 1 |
| Liu, Z | 1 |
| Qin, Y | 1 |
| Wu, M | 1 |
| Liu, Y | 1 |
| Ren, L | 1 |
| Koch, HG | 1 |
| Kaiser, B | 1 |
| Potempa, LA | 1 |
| Mellett, NA | 1 |
| Miles, LA | 1 |
| Du, XJ | 1 |
| Meikle, PJ | 1 |
| Huber-Lang, M | 1 |
| Hoel, TN | 2 |
| Thiara, AS | 2 |
| Videm, V | 2 |
| Fiane, AE | 2 |
| Mollnes, TE | 2 |
| Castellheim, A | 1 |
| Svennevig, JL | 1 |
| Fox, LM | 1 |
| Cox, DG | 1 |
| Lockridge, JL | 1 |
| Chen, X | 1 |
| Scharf, L | 1 |
| Trott, DL | 1 |
| Ndonye, RM | 1 |
| Veerapen, N | 1 |
| Besra, GS | 1 |
| Howell, AR | 1 |
| Cook, ME | 1 |
| Adams, EJ | 1 |
| Hildebrand, WH | 1 |
| Gumperz, JE | 1 |
| Kim, HJ | 1 |
| Kim, KM | 1 |
| Koh, JY | 1 |
| Noh, MS | 1 |
| Park, MK | 1 |
| Lee, HJ | 1 |
| Kim, SY | 1 |
| Lee, CH | 1 |
| Bäumer, W | 1 |
| Wlaź, P | 1 |
| Jennings, G | 1 |
| Rundfeldt, C | 1 |
| Andersen, VY | 1 |
| Svennevig, K | 1 |
| Dölle, S | 1 |
| Hoser, D | 1 |
| Rasche, C | 1 |
| Loddenkemper, C | 1 |
| Maurer, M | 1 |
| Zuberbier, T | 1 |
| Worm, M | 1 |
| Wirrig, C | 1 |
| Hunter, I | 1 |
| Mathieson, FA | 1 |
| Nixon, GF | 1 |
| Tugirimana, PL | 1 |
| De Clercq, D | 1 |
| Holderbeke, AL | 1 |
| Kint, JA | 1 |
| De Cooman, L | 1 |
| Deprez, P | 1 |
| Delanghe, JR | 1 |
| Rahman, I | 1 |
| Atout, R | 1 |
| Pedersen, NL | 1 |
| de Faire, U | 1 |
| Ninio, E | 1 |
| Bennet, AM | 1 |
| Magnusson, PK | 1 |
| Al-Riyami, L | 1 |
| Harnett, W | 2 |
| Paparella, D | 1 |
| Scrascia, G | 1 |
| Rotunno, C | 1 |
| Marraudino, N | 1 |
| Guida, P | 1 |
| De Palo, M | 1 |
| Rubino, G | 1 |
| Cappabianca, G | 1 |
| Algarra, M | 1 |
| Gomes, D | 1 |
| Esteves da Silva, JC | 1 |
| Iwasaki, Y | 1 |
| Sawada, S | 1 |
| Ishihara, K | 1 |
| Khang, G | 1 |
| Lee, HB | 1 |
| Saraiva, VB | 1 |
| Gibaldi, D | 1 |
| Previato, JO | 1 |
| Mendonça-Previato, L | 1 |
| Bozza, MT | 1 |
| Freire-De-Lima, CG | 1 |
| Heise, N | 1 |
| Long, SF | 1 |
| Clarke, S | 1 |
| Davies, MC | 1 |
| Lewis, AL | 2 |
| Hanlon, GW | 1 |
| Lloyd, AW | 2 |
| Huang, Y | 1 |
| Liu, X | 1 |
| Verbeken, E | 1 |
| Li, S | 1 |
| De Scheerder, I | 1 |
| Goreish, HH | 1 |
| Rose, S | 1 |
| Black, S | 1 |
| Kushner, I | 1 |
| Samols, D | 1 |
| Goodridge, HS | 1 |
| Marshall, FA | 1 |
| Wilson, EH | 1 |
| Houston, KM | 1 |
| Liew, FY | 1 |
| Harnett, MM | 1 |
| Draaisma, AM | 1 |
| Hazekamp, MG | 1 |
| Anes, N | 1 |
| Schoof, PH | 1 |
| Hack, CE | 1 |
| Sturk, A | 1 |
| Dion, RA | 1 |
| Berrocal, DH | 1 |
| González, GE | 1 |
| Morales, C | 1 |
| Gelpi, RJ | 1 |
| Grinfeld, LR | 1 |
| Wiswell, TE | 1 |
| Peabody, SS | 1 |
| Davis, JM | 1 |
| Slayter, MV | 1 |
| Bent, RC | 1 |
| Merritt, TA | 1 |
| De Somer, F | 1 |
| François, K | 1 |
| van Oeveren, W | 1 |
| Poelaert, J | 1 |
| De Wolf, D | 1 |
| Ebels, T | 1 |
| Van Nooten, G | 1 |
| Saxena, U | 1 |
| Nagpurkar, A | 1 |
| Mookerjea, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
10 reviews available for phosphorylcholine and Inflammation
| Article | Year |
|---|---|
Systemic lupus erythematosus and cardiovascular disease.
Topics: Antibodies, Antiphospholipid; Atherosclerosis; Cardiovascular Diseases; Humans; Inflammation; Lupus | 2023 |
Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity.
Topics: C-Reactive Protein; Calcium; Cytokines; Humans; Inflammation; Ligands; Phosphorylcholine; Protein Co | 2022 |
C-reactive protein, immunothrombosis and venous thromboembolism.
Topics: Biomarkers; C-Reactive Protein; COVID-19; Humans; Inflammation; Phosphorylcholine; Protein Isoforms; | 2022 |
The OSE complotype and its clinical potential.
Topics: C-Reactive Protein; Complement C1q; Complement Factor H; Epitopes; Humans; Immunoglobulin M; Immunol | 2022 |
Updates on the epidemiology, pathogenesis, diagnosis, and management of postinfectious irritable bowel syndrome.
Topics: Adult; Animals; Anti-Bacterial Agents; Child; Colon; Gastroenteritis; Humans; Infections; Inflammati | 2020 |
Tuftsin phosphorylcholine-a novel compound harnessing helminths to fight autoimmunity.
Topics: Animals; Autoimmune Diseases; Autoimmunity; Helminthiasis; Helminths; Humans; Inflammation; Phosphor | 2018 |
Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes.
Topics: Animals; C-Reactive Protein; Hexanes; Humans; Inflammation; Phosphorylcholine; Protein Conformation | 2015 |
Immunomodulatory properties of ES-62, a phosphorylcholine-containing glycoprotein secreted by Acanthocheilonema viteae.
Topics: Animals; Dipetalonema; Helminth Proteins; Humans; Immunologic Factors; Immunomodulation; Inflammatio | 2012 |
Current analytical strategies for C-reactive protein quantification in blood.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Ethanolamines; High-Throughput Screening As | 2013 |
C-reactive Protein.
Topics: Animals; Arteriosclerosis; C-Reactive Protein; Complement C1q; Gene Expression Regulation; Humans; I | 2004 |
6 trials available for phosphorylcholine and Inflammation
| Article | Year |
|---|---|
Oxidant Status following Cardiac Surgery with Phosphorylcholine-Coated Extracorporeal Circulation Systems.
Topics: Coronary Artery Bypass; Demography; Extracorporeal Circulation; Female; Humans; Inflammation; Interl | 2016 |
Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response.
Topics: Aged; Anticoagulants; Antithrombin III; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coated | 2010 |
Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis.
Topics: Administration, Topical; Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Derma | 2010 |
A biocompatible cardiopulmonary bypass strategy to reduce hemostatic and inflammatory alterations: a randomized controlled trial.
Topics: Aged; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Hemostasis; Humans; Inflammation; Male | 2012 |
Phosphorylcholine coating of bypass systems used for young infants does not attenuate the inflammatory response.
Topics: Cardiopulmonary Bypass; Complement Activation; Double-Blind Method; Equipment Design; Female; Humans | 2006 |
Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface.
Topics: beta-Thromboglobulin; Blood Coagulation; Cardiopulmonary Bypass; CD18 Antigens; Cell Adhesion; Compl | 2000 |
39 other studies available for phosphorylcholine and Inflammation
| Article | Year |
|---|---|
Anterior Scleral and Limbal Inflammatory Necrosis After Adjuvant Miltefosine for Recalcitrant Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Adjuvants, Immunologic; Adult; Humans; Inflammation; Necrosis; Phosphorylcho | 2022 |
Antibodies against phosphorylcholine and protection against atherosclerosis, cardiovascular disease and chronic inflammation.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Humans; Immunoglobulin G; Immunoglobulin M; Infla | 2022 |
Sphingosylphosphorylcholine ameliorates experimental sjögren's syndrome by regulating salivary gland inflammation and hypofunction, and regulatory B cells.
Topics: Animals; B-Lymphocytes, Regulatory; Disease Models, Animal; Female; Humans; Inflammation; Mice; Mice | 2022 |
Systemic and Ocular Anti-Inflammatory Mechanisms of Green Tea Extract on Endotoxin-Induced Ocular Inflammation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Endotoxins; Inflammation; Lipopolysaccharides; Phos | 2022 |
Impact of Olive Oil Constituents on C-reactive Protein: In silico Evidence.
Topics: Anti-Inflammatory Agents; C-Reactive Protein; Humans; Inflammation; Molecular Docking Simulation; Ol | 2022 |
A novel phosphocholine-mimetic inhibits a pro-inflammatory conformational change in C-reactive protein.
Topics: Anti-Inflammatory Agents; C-Reactive Protein; Cell Membrane; Humans; Inflammation; Phosphorylcholine | 2023 |
A novel phosphocholine-mimetic inhibits a pro-inflammatory conformational change in C-reactive protein.
Topics: Anti-Inflammatory Agents; C-Reactive Protein; Cell Membrane; Humans; Inflammation; Phosphorylcholine | 2023 |
A novel phosphocholine-mimetic inhibits a pro-inflammatory conformational change in C-reactive protein.
Topics: Anti-Inflammatory Agents; C-Reactive Protein; Cell Membrane; Humans; Inflammation; Phosphorylcholine | 2023 |
A novel phosphocholine-mimetic inhibits a pro-inflammatory conformational change in C-reactive protein.
Topics: Anti-Inflammatory Agents; C-Reactive Protein; Cell Membrane; Humans; Inflammation; Phosphorylcholine | 2023 |
Bioinspired Hyaluronic Acid/Phosphorylcholine Polymer with Enhanced Lubrication and Anti-Inflammation.
Topics: Animals; Biocompatible Materials; Cartilage, Articular; Friction; Humans; Hyaluronic Acid; Inflammat | 2019 |
The anti-parasitic drug miltefosine suppresses activation of human eosinophils and ameliorates allergic inflammation in mice.
Topics: Animals; Eosinophils; Humans; Inflammation; Mice; Ovalbumin; Parasites; Pharmaceutical Preparations; | 2021 |
Collagen analogs with phosphorylcholine are inflammation-suppressing scaffolds for corneal regeneration from alkali burns in mini-pigs.
Topics: Alkalies; Animals; Biocompatible Materials; Burns, Chemical; Collagen; Cornea; Humans; Hydrogels; In | 2021 |
Phosphorylcholine antibodies restrict infarct size and left ventricular remodelling by attenuating the unreperfused post-ischaemic inflammatory response.
Topics: Animals; Antibodies, Monoclonal; Apolipoprotein E3; Disease Models, Animal; Female; Inflammation; Is | 2021 |
Synergistic Anti-inflammatory Coating "Zipped Up" on Polypropylene Hernia Mesh.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biofouling; Cell Line; Coated Materials, Biocompati | 2021 |
(E)-2-Methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) phenol attenuates PMA-induced inflammatory responses in human monocytic cells through PKCδ/JNK/AP-1 pathways.
Topics: Anti-Inflammatory Agents; Cell Line; Cyclooxygenase 2; Down-Regulation; Humans; Inflammation; MAP Ki | 2018 |
Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice.
Topics: Animals; Aortic Valve Stenosis; Apoptosis; Atherosclerosis; Cholesterol; Disease Progression; Fatty | 2018 |
C-Reactive Protein Promotes Inflammation through FcγR-Induced Glycolytic Reprogramming of Human Macrophages.
Topics: Atherosclerosis; C-Reactive Protein; Cells, Cultured; Cellular Reprogramming; Cytokines; Glycolysis; | 2019 |
IgM anti-phosphorylcholine antibodies associate with senescent and IL-17+ T cells in SLE patients with a pro-inflammatory lipid profile.
Topics: Adult; Atherosclerosis; Autoantibodies; Biomarkers; Carotid Arteries; Female; Humans; Immunoglobulin | 2020 |
The scavenger receptor CD36 downmodulates the early inflammatory response while enhancing bacterial phagocytosis during pneumococcal pneumonia.
Topics: Animals; CD36 Antigens; Disease Models, Animal; Female; Immunity, Innate; Inflammation; Macrophages, | 2013 |
Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cytokines; Disease Models, Animal; Humans; Immun | 2013 |
Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy.
Topics: Animals; Anti-Inflammatory Agents; Biopolymers; C-Reactive Protein; Carrier Proteins; Cell Adhesion; | 2014 |
Essential Role of Lysophosphatidylcholine Acyltransferase 3 in the Induction of Macrophage Polarization in PMA-Treated U937 Cells.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Cell Differentiation; Cell Polarity; Gene Expression | 2015 |
Increased Levels of Sphingosylphosphorylcholine (SPC) in Plasma of Metabolic Syndrome Patients.
Topics: Biomarkers; Female; Humans; Inflammation; Lipids; Lysophospholipids; Male; Metabolic Syndrome; Middl | 2015 |
Improvement of Uveal and Capsular Biocompatibility of Hydrophobic Acrylic Intraocular Lens by Surface Grafting with 2-Methacryloyloxyethyl Phosphorylcholine-Methacrylic Acid Copolymer.
Topics: Adsorption; Animals; Anterior Capsule of the Lens; Biocompatible Materials; Cataract; Cataract Extra | 2017 |
Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites.
Topics: Amino Acid Sequence; Animals; Binding Sites; C-Reactive Protein; Gene Expression Regulation; Hexanes | 2017 |
[Small fatty substances may be of great importance in the development of atherosclerosis].
Topics: Antibodies; Atherosclerosis; Humans; Inflammation; Malondialdehyde; Phosphorylcholine | 2017 |
In vitro evaluation of PHISIO-coated sets for pediatric cardiac surgery.
Topics: Biomarkers; Blood Coagulation; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Child; Coated Ma | 2009 |
Recognition of lyso-phospholipids by human natural killer T lymphocytes.
Topics: Antigen Presentation; Antigen-Presenting Cells; Antigens, CD1d; Autoantigens; Cell Line; Cytokines; | 2009 |
Sphingosylphosphorylcholine induces degranulation of mast cells in the skin and plasma exudation in the ears of mice.
Topics: Animals; Dermatitis; Dose-Response Relationship, Drug; Ear; Histamine; Inflammation; Mast Cells; Mic | 2010 |
The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Arachidonic Acid; | 2010 |
Sphingosylphosphorylcholine is a proinflammatory mediator in cerebral arteries.
Topics: Animals; Blood Platelets; Blotting, Western; Cells, Cultured; Cerebral Arteries; Chemokine CCL2; Ele | 2011 |
A functional turbidimetric method to determine C-reactive protein in horses.
Topics: Animals; Blood Cell Count; C-Reactive Protein; Cohort Studies; Horse Diseases; Horses; Inflammation; | 2011 |
Genetic and environmental regulation of inflammatory CVD biomarkers Lp-PLA2 and IgM anti-PC.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Biomarkers; Cardiovascular Diseases; Diseases | 2011 |
Reduction of surface-induced inflammatory reaction on PLGA/MPC polymer blend.
Topics: 3T3 Cells; Actins; Animals; Biocompatible Materials; Cell Adhesion; Electron Probe Microanalysis; Fo | 2002 |
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.
Topics: Animals; Antiprotozoal Agents; Chagas Disease; Drug Resistance; Exudates and Transudates; Inflammati | 2002 |
Controlled biological response on blends of a phosphorylcholine-based copolymer with poly(butyl methacrylate).
Topics: Adsorption; Animals; Biocompatible Materials; Cell Adhesion; Cell Division; Epithelial Cells; Humans | 2003 |
Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model.
Topics: Animals; Anti-Inflammatory Agents; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompat | 2003 |
The effect of phosphorylcholine-coated materials on the inflammatory response and fibrous capsule formation: in vitro and in vivo observations.
Topics: Capsules; Coated Materials, Biocompatible; Humans; Inflammation; Muscle, Skeletal; Phosphorylcholine | 2004 |
In vivo exposure of murine dendritic cell and macrophage bone marrow progenitors to the phosphorylcholine-containing filarial nematode glycoprotein ES-62 polarizes their differentiation to an anti-inflammatory phenotype.
Topics: Animals; Cell Differentiation; Cells, Cultured; Cytokines; Dendritic Cells; Helminth Proteins; Infla | 2004 |
Irinotecan-eluting stents inhibited neointimal proliferation in hypercholesterolemic rabbit aortas.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Camptothecin; Cell Proliferation; Dietary Fats; Disease | 2006 |
Surfactant therapy and high-frequency jet ventilation in the management of a piglet model of the meconium aspiration syndrome.
Topics: Animals; Animals, Newborn; Biological Products; Bronchoalveolar Lavage Fluid; Disease Models, Animal | 1994 |
Contrasting effect of phosphorylcholine-binding protein from rat and rabbit on heparin-lipoprotein interaction: a role of sialic acid.
Topics: Animals; Calcium; Carrier Proteins; Chemical Precipitation; Choline; Drug Interactions; Electrophore | 1985 |